- Open Access
Functionalized MoS2-erlotinib produces hyperthermia under NIR
Journal of Nanobiotechnologyvolume 17, Article number: 76 (2019)
Molybdenum disulfide (MoS2) has been widely explored for biomedical applications due to its brilliant photothermal conversion ability. In this paper, we report a novel multifunctional MoS2-based drug delivery system (MoS2-SS-HA). By decorating MoS2 nanosheets with hyaluronic acid (HA), these functionalized MoS2 nanosheets have been developed as a tumor-targeting chemotherapeutic nanocarrier for near-infrared (NIR) photothermal-triggered drug delivery, facilitating the combination of chemotherapy and photothermal therapy into one system for cancer therapy.
The nanocomposites (MoS2-SS-HA) generated a uniform diameter (ca. 125 nm), exhibited great biocompatibility as well as high stability in physiological solutions, and could be loaded with the insoluble anti-cancer drug erlotinib (Er). The release of Er was greatly accelerated under near infrared laser (NIR) irradiation, showing that the composites can be used as responsive systems, with Er release controllable through NIR irradiation. MTT assays and confocal imaging results showed that the MoS2-based nanoplatform could selectively target and kill CD44-positive lung cancer cells, especially drug resistant cells (A549 and H1975). In vivo tumor ablation studies prove a better synergistic therapeutic effect of the joint treatment, compared with either chemotherapy or photothermal therapy alone.
The functionalized MoS2 nanoplatform developed in this work could be a potent system for targeted drug delivery and synergistic chemo-photothermal cancer therapy.
Cancer is one of the biggest challenges that threaten human health, among which lung and bronchus are the most common cause of cancer-related death [1,2,3]. Chemotherapy is still one of the frequently used therapeutic modalities for cancer treatment over the past decades, however chemotherapy suffers from several therapeutic bottlenecks, such as severe side effects, low solubility, and the tendency to induce drug resistance [4, 5]. Erlotinib (Er) is a clinical anticancer drugs working by selectively and reversibly inhibiting the epidermal growth factor receptor (EGFR) tyrosine kinase , thereby inhibiting downstream signaling pathways such as cell proliferation, metastasis, and angiogenesis . Although Er has shown strong clinical therapeutic effect for lung cancer, the tumor therapeutic activity is still limited by above bottlenecks of chemotherapy, especially low solubility, instability and drug resistance. Therefore, it is necessary to develop an Er delivery system to overcome these defects and enhance its bioavailability.
Recently, a multitude of nanomaterials have been designed as they exhibit promising potential to overcome the limitations of chemotherapy drugs for cancer therapy applications, such as liposomes , carbon nanomaterials , silica nanoparticles , metal-based nanoparticles , polymeric nanoparticles [12,13,14] and quantum dots [15, 16] have been used in biomedical applications. Compared to these nanomaterials, two-dimensional (2D) nanomaterials possess exceptional chemical, optical, and electronic properties and are thus, being considered as novel therapeutic agents for biomedicine, especially for cancer treatment. There have been some particularly interesting reports that demonstrate encouraging potential of 2D nanomaterial theranostics in the pre-clinical area and targeted delivery of cancer therapeutics [12,13,14,15,16,17]. Since graphene oxide was applied, single layer 2D nanomaterials has drawn much attention in a wide range of areas because of their unique physical and chemical properties. Owing to these excellent properties, more effort has been paid to search for other similar 2D materials [17, 18]. MoS2 nanosheets, as a kind of transition metal dichalcogenides (TMDCs), displayed huge potential applications for nanoelectronic [19,20,21], transistors [22,23,24], energy storage devices [25, 26] and catalysis [27,28,29]. Past several years, a few groups have explored the promising application of single-layer MoS2 sheets in the biomedical field [30, 31]. Photothermal therapy (PTT) as a non-invasive therapeutic approach triggered by light, can transfer optical energy into heat, resulting in the thermal ablation of cancer cells [32, 33]. As a new type of 2D TMDCs, MoS2 has exhibited its intrinsic high NIR absorbance as well as outstanding photothermal conversion efficiency, which indicated that MoS2 could be used as a photothermal agent (PTA) for PTT [31, 34,35,36]. Besides, as a NIR photothermal delivery system, MoS2 has been reported that could stimulate the drug release triggered by NIR irradiation [37, 38]. Hence, the MoS2-nanosheets could be used to form a NIR-triggered drug delivery system because of the larger surface area and amazing photothermic. However, MoS2 nanosheets rapidly aggregate in physiological solution, which hampers the application of MoS2 nanosheets in the medical field. Therefore, the surface modification of single-layer MoS2 nanosheet remains a tremendous challenge for the application of the MoS2 nanosheets in biomedicine. Chou et al. showed that the thiolated molecules could be attached to the MoS2 nanosheets at the defect sites resulted from chemical exfoliation process and reported that the modified single-layer MoS2 sheets show outstanding biocompatibility and high absorbance when under the irradiation of NIR laser [34, 39]. The novel approach for the surface modification of single-layer MoS2 nanosheet is urgently needed.
Hyaluronic acid (HA), as a water-soluble biomacromolecule, has great biocompatibility and biodegradability [40, 41], Besides, HA is also a natural ligand for CD44 that is often overexpressed by various cancer cells, especially in drug-resistance cancer cells, and has been widely used in active targeting treatment of lung cancer [42,43,44]. MoS2 nanosheet modified with HA not only enhances its stability in physiological solution, but also could specifically combine with the drug-resistant tumor cells which overexpress CD44 . Hence, this study was designed to demonstrate that Er-loaded MoS2 modified with HA could be engineered as a photothermal-triggered drug delivery system to specially target the CD44-overexpressing cancer cells, deliver non-water-soluble drug Er into cells, produce NIR-mediated hyperthermia, stimulate drug release triggered by photothermic, resulting in a synergistic cancer therapeutic effect in vitro and in vivo.
Materials and methods
Molybdenum sulfide (MoS2, 99%) was purchased from Sigma Aldrich (CA, USA). Cystamine dihydrochloride was bought from Bide Pharmatech Co., Ltd (Shanghai, China). Hyaluronic acid (MW = 35 kDa) was purchased from Shandong Freda biological Technology Co., Ltd (Jinan, China). Erlotinib (Er, 99%) was provided by Dalian Meilun biological Technology Co., Ltd (Dalian, China). All reagents related to cell culture were purchased from Hyclone (Logan, UT, USA). Other reagents were obtained from J&K Scientific Ltd (Shanghai, China). All the chemicals were used as received without further purification.
Preparation of single-layer MoS2-SS-HA nanosheets
Synthesis of MoS2 nanosheets
MoS2 nanosheets were synthesized by using the Morrison method . In brief, 0.5 g MoS2 flakes were stirred with a solution of n-butyllithium in hexane (0.5 mL; 1.6 M) under N2 atmosphere for 48 h, performed in a nitrogen glove box. After intercalation by lithium, the sample was centrifuged and washed repeatedly with hexane to remove leftover lithium and additional organic residues. Intercalated MoS2 solution was then dislodged from the glove box and instantly ultra-sonicated in water for 1 h to obtain exfoliated MoS2, besides, the unexfoliated MoS2 and excess LiOH were removed by centrifugation at 3000 rpm. The supernatant containing exfoliated MoS2 was dialyzed against water for 48 h to remove excess impurities and the finally obtained MoS2 nanosheets aqueous solution was stored at 4 °C for future use.
Preparation of targeted nanocomposite
200 mg HA was first dissolved in 20 mL deionized water, then 38 mg ethylene dichloride (EDC) and 46 mg N-hydroxysuccinimide (NHS) were added under stirring. Afterwards cystamine dihydrochloride (1.2 g) was added to the mixture and stirred overnight. The product, denoted HA-SS, was obtained after dialyzing against water with a cellulose membrane (MWCO: 1 kDa) for 24 h. 5 mg HA-SS was added to a dispersion of MoS2 (0.25 mg/mL, 4 mL water) and then ultrasonicated for 30 min. After stirring overnight, the resultant product (MoS2-SS-HA) was dialyzed with water against a cellulose membrane (MWCO: 100 kDa). The obtained MoS2-SS-HA nanosheets were stored at 4 °C until use.
Erlotinib loading and releasing
Erlotinib (Er) loading onto MoS2-SS-HA was applied according to the following protocol. In brief, MoS2-SS-HA nanosheets watery solution (0.5 mg/mL) was mixed with different concentrations of Er which were dissolved in DMSO solution and stirring the mixture for 24 h (pH = 7.0). Excess Er was removed by centrifugation at 4000 rpm for 20 min. The supernatant was filtered (0.45 μm) to remove the remaining undissolved Er. The obtained solution was centrifuged for 5 times by ultrafiltration (10 kDa MWCO) to remove the dissolved excess Er. Loading amount of Er was detected using UV–vis spectra absorbance peak at 343 nm.
The methods were similar to what we described previous [47,48,49]. Briefly, 2.5 mg MoS2-SS-HA-Er nanosheets were suspended in PBS buffer (5 mL, pH = 7.4) or acetate buffer (5 mL, pH = 5.6) and placed into dialysis bags (10 kDa MWCO). After 1 h, the samples were irradiated by 808 nm NIR laser with a power density of 1 W/cm2 for 20 min. The release assay was performed on a shaking bed at 37 °C at a speed of 100 rpm. Each of 0.5 mL dialysate was collected at designed time points and replaced with the same volume of fresh buffer solution. The released amount of Er from MoS2-SS-HA-Er was quantified by UV–Vis spectroscopy. The accumulative amount of Er released from the composites was calculated as follows:
The morphology of MoS2 was measured using transmission electron microscopy (TEM; JEM-2100, JEOL). The thickness and size of the MoS2 particles were determined with a 5500 atomic force microscope (AFM; Agilent). The zeta potential was quantified with a ZS90 Zetasizer instrument (Malvern Instruments). Dynamic light scattering (DLS) was performed with static light scattering instrument (BI-200SM, Brookhaven Instruments). UV–vis spectra were obtained on a UV3600 instrument (Shimadzu Corporation). Fourier transform infrared (FT-IR) spectroscopy was recorded on a Vetex70 (Bruker Corp., Germany). The photothermal properties of the composite were examined using a laser device (Shanghai Xilong Optoelectronics Technology Co. Ltd.) at a wavelength of 808 nm.
A549 (EGFR wide-type, erlotinib-initially resistant), H1975 (EGFR-mutated subtype, L858R/T790M double mutations, erlotinib-acquired resistant), PC-9 (EGFR-mutated subtype, exon 19 deletion, erlotinib-sensitive) and HELF cells were purchased from the Cell Resource Center of Shanghai Institute for Biological Sciences (Chinese Academy of Sciences, Shanghai, China). These cells were cultured in the recommended medium at 37 °C within 5% CO2 atmosphere.
Biocompatibility of MoS2-SS-HA in vitro and in vivo
Cytotoxicity assays in vitro
The methods were described in our previous study . In brief, cells were seeded in 96-well cell culture plates at a density of 8 × 103 cells/well and incubated with MoS2-SS-HA at different concentrations (12.5, 25, 50, 100, 200 μg/mL). After 24 h incubation, the cells viabilities were measured by MTT assay.
Hemolysis assays of MoS2-SS-HA in vivo
Hemolysis assay were performed as following: 1 mL blood obtained from rat (Wistar, female, 4–6 weeks old, purchased from Fuzhou Wushi Animal Center) was treated with ethylene diamine tetracetic acid. Then the blood was centrifuged at 1000 rpm for 10 min and removed the upper serum carefully. The lower red blood cells were diluted 30 times with PBS. Next, 0.3 mL of diluted red blood cells was mixed with (i) 0.9 mL of PBS as a negative control, (ii) 0.9 mL of water as a positive control, (iii) 0.9 mL of MoS2-SS-HA dispersions at different concentrations (50, 100, 200, 400, 800 μg/mL). Eventually, all the mixtures were kept shaking at 100 rpm for 2 h and then centrifuged at 12,000 rpm for 10 min. The absorbance of supernatants was detected at 541 nm by UV–vis spectrophotometry. Hemolysis percentage (%) = (A sample-A negative)/(A positive-A negative) × 100%.
Biocompatibility of assays in vivo
Biocompatibility of MoS2-SS-HA was carried out in vivo in accordance with the protocol approved by Institutional Animal Care and Use Committee. BALB/c nude female mice (5–7 weeks old) were purchased from Fuzhou Wushi Animal Center and maintained in cages in a SPF-grade animal room with access to food and water ad libitum. After 1 week of adaptation feeding, nude mice were randomly divided into two groups (n = 5), then nude mice were treated with 100 μL of (i) saline, (ii) MoS2-SS-HA in saline (2.0 mg/kg), via tail vein injection. The injection was performed every 2 days. After 3 weeks, all mice were sacrificed and the major organs (heart, liver, spleen, lung and kidney) were obtained and were stained with hematoxylin–eosin (H&E) to observe histopathological changes.
In vitro cellular uptake
Intracellular uptake of the FITC-loading MoS2-SS-HA nanosheets was judged by confocal laser scanning microscopy (CLSM, Leica TCS SP8, IL, USA) and flow cytometry (BD FACSAriaIII, BD Bioscience). As a fluorescent probe, the FITC was loaded on the MoS2-SS-HA nanosheets in the same protocol as Er (shown in 2.3.1 Er loading procedure). Cells were seeded in 6-well plates (1 × 105 cells/well) and cultured for 24 h. The media was aspirated and 2 mL of fresh DMEM containing 0 or 5 mg/mL HA was added. 2 h later, cells were washed twice with PBS and incubated with MoS2-SS-HA-FITC (FITC = 5 μg/mL). The cells in all the groups were cultured for another 2 h and then washed and fixed with glutaraldehyde for 30 min. The cell nuclei were stained with DAPI and detected by CLSM and flow cytometry.
Cytotoxicity of MoS2-SS-HA-Er in vitro
The cytotoxicity of MoS2-SS-HA-Er against lung cancer cells (A549, H1975, PC-9) was assessed by MTT assay. Briefly, cells were seeded in 96-well plates and cultured overnight. Then media was aspirated and a solution of Er (200 μL, [Er] = 1.25, 2.5, 5, 10, 20 μg/mL) were added to each well, and the plates incubated at 37 °C in a 5% CO2 atmosphere for 24 h. The MTT reagent (10 μL, 5 mg/mL) was then added, followed by incubation at 37 °C in a 5% CO2 atmosphere for 4 h. The supernatant was then carefully removed and the MTT-formazan produced by live cells solubilized in 150 mL of DMSO for 20 min. Finally, the absorbance at 490 nm was measured using a microplate reader (MULTSIKAN MK3, Thermo Fisher). Cell viability (%) was determined from the absorbance at 490 nm and normalized to a negative control wells containing untreated cells. Experiments were performed in triplicate.
A second set of experiments was performed to assess the potential for photochemo-therapies. Cells were cultured in a 96-well plate at 1 × 104 cells per well (200 μL of cell suspension per well) for 24 h, and then co-cultured with Er or MoS2-SS-HA-Er. Cells were divided into 4 treatment groups at Er concentrations ranging from 1.25 to 20 μg/mL as follows: (i) Saline + NIR; (ii) Free Er + NIR; (iii) MoS2-SS-HA-Er + NIR (synergistic therapy); (iv). MoS2-SS-HA + NIR. After incubation for 12 h, the cells were washed with 100 μL PBS and 100 μL culture medium was then added to the wells. The cells were irradiated with an 808 nm laser at different power densities (0.5 W, 0.8 W, 1.2 W) for 20 min, before the cells were cultured for a further 24 h and an MTT assay used to measure cell viability.
Detection of cell apoptosis and cell cycle
To evaluate the therapeutic efficacy of the nanosheets, cell cycle and apoptosis were measured by using flow cytometry according to following protocol. Briefly, cells were seeded at a density of 3 × 105 cells/well in the six-well plates. After 24 h, the cells were separated into five groups, as following: control, Er, MoS2-SS-HA + NIR, MoS2-SS-HA-Er and MoS2-SS-HA-Er + NIR ([Er] = 10 μg/mL). Besides, groups of MoS2-SS-HA + NIR and MoS2-SS-HA-Er + NIR were exposed to 808 nm-NIR laser with a power density of 1.2 W/cm2 for 20 min. Finally, the cells were collected and detected by flow cytometry according to the instruction of Apoptosis Assay Kits (Keygen BioTech, Nanjing, China). For cell cycle assay, the cells were collected and washed thrice with ice-cold PBS. Then the cells were fixed with cold 70% ethanol for 24 h at 4 °C. Subsequently, the cells were centrifuged and washed twice with PBS. Ultimately, the staining solution consisting of 1% (v/v) Triton X-100, 0.01% RNase, and 0.05% PI was added to the cells and stained for 30 min in darkness before detection by flow cytometry.
Antitumor effects of MoS2-SS-HA-Er in vivo
All animal experiments were carried out in accordance with the protocol approved by Institutional Animal Care and Use Committee. BALB/c nude female mice (5–7 weeks old) were purchased from Fuzhou Wushi Animal Center and maintained in cages in a SPF-grade animal room with access to food and water ad libitum. A549 cells (1 × 106 cells/well) were suspended in 100 μL PBS were subcutaneously injected into the left fore limb of each nude mouse to form the tumor model. The tumor volume was measured using vernier caliper and calculated as V = (length × width2)/2. The nude mice were randomly divided into six groups (n = 5) when the tumor volume reached up to 90 mm3. Afterward, each group of the tumor-bearing nude mice was treated with 100 μL of (i) saline, (ii) Er (2.0 mg/kg), (iii, iv) MoS2-SS-HA in saline (2.0 mg/kg), and (v, vi) MoS2-SS-HA-Er (2.0 mg/kg) in saline, respectively, via tail vein injection. After 8 h, the mice of group (iv) and (vi) were treated with 808 nm-NIR laser light (0.5 W/cm2) for 10 min. The infrared ray (IR) images of tumors were observed with an infrared thermal camera (InfReC R500EX, Tokyo, Japan), showing the real-time temperature changes with irradiation. During the treatment, the tumors volume and the weight of mice were recorded every 3 days.
Statistical analysis was performed with GraphPad Prism 5.0 (GraphPad software, San Diego, CA). In general, for two experimental comparisons, a two-tailed unpaired Student’s t test was used unless otherwise indicated. For multiple comparisons, one-way ANOVAs were applied. When cells were used for experiments, three replicates per treatment were chosen as an initial sample size. All n values defined in the legends refer to biological replicates. Data were assessed as mean ± SD. Statistical significance was set at *p < 0.05 and high significance was set at **p < 0.01.
Result and discussion
Preparation and characterization of nanocomposites
Figure 1 demonstrates the preparation of HA-modified MoS2 nanosheets as a multifunctional nano-platform for targeted and photothermal-responsive therapy of tumor. First, the single-layer MoS2 nanosheet was prepared following the method of chemical exfoliation . Then HA was decorated on the surface of single-layer MoS2 nanosheet with the cystamine dihydrochloride to form MoS2-SS-HA. Finally, Er was loaded on the surface of MoS2-SS-HA to obtain MoS2-SS-HA-Er. This nanosheets integrates the multifunction of insoluble drug targeted delivery, PTT and controlled drug release.
The typical morphologies, structures, and dispersity of MoS2, MoS2-SS-HA and MoS2-SS-HA-Er were analyzed by transmission electron microscopy (TEM). In Fig. 2a, it is shown that MoS2 nanosheets have a well-defined laminar morphology with a size of around 70 nm, while MoS2-SS-HA and MoS2-SS-HA-Er have a wrinkled sheets and larger-size (125 nm), which are usually observed for modification of nanosheets. The morphology of prepared MoS2-SS-HA was characterized by AFM images, which shows the material to consist of exfoliated sheets (Fig. 2b), the results are consist with the literature of MoS2 . The AFM data in Fig. 2c, show that the thickness of MoS2 nanosheets is approximately 0.7 nm, indicating that the acquired nanosheet was single layer . The height of nanosheets increased to about 2 nm after HA coating, revealing the successful coating of HA on the surface of MoS2 nanosheets. The hydrodynamic diameters of the nanocomposites were quantified by DLS, and the results are shown in Fig. 2d. The hydrodynamic diameters of MoS2 and MoS2-SS-HA nanosheets detected by DLS were 75 nm and 125 nm, respectively, which is appropriate for use as cell-targeted drug delivery system.
Zeta potential of MoS2, MoS2-SS-HA and MoS2-SS-HA-Er were shown in Fig. 2e. The zeta potential of MoS2-SS-HA is − 24.8 mV (HA-SS is − 17.3 mV and MoS2 is − 47.7 mV), there is no significant difference between MoS2-SS-HA and MoS2-SS-HA-Er in accordance with literature . UV–vis spectroscopy further validated the successful synthesis of MoS2-SS-HA-Er (Fig. 2f). The characteristic peak of MoS2 is between 260 to 300 nm. The characteristic peak of HA is around 192 nm, similar to literatures [54, 55]. The characteristic peak of Er is around 335 nm in accordance with references [56, 57]. MoS2-SS-HA-Er showed both characteristic peaks of HA and Er.
As expected, physiological stability of MoS2 nanosheets was improved after modified with HA. In addition, the MoS2 nanosheets generated obvious aggregation among in water, PBS and cell medium within 1 h, while no obvious aggregation was observed in water and other physiological solutions for 1 month after decorated with HA, which demonstrated the good dispersibility of MoS2-SS-HA and MoS2-SS-HA-Er in physiological solutions (Fig. 2g). To confirm the combination of Er and MoS2-SS-HA sheets, Fourier transform infrared (FT-IR) spectroscopy was conducted. As shown in Fig. 2h, the amide group (–CO–NH–) of HA appears as a characteristic band at about 1600 cm−1, and the band at 3431.03 cm−1 correspond to the characteristic vibration of the –C≡H bond due to the coupling vibration of Er.
It is well known that MoS2 nanocomposites have good photothermal conversion efficiency [58, 59], and hence the photothermal activity of MoS2-SS-HA was explored in a series of tests. In Fig. 3a1, the photothermal heating effect of a 50 μg/mL suspension of the MoS2-SS-HA composite under irradiation by different laser power is depicted. A laser power intensity dependent photothermal effect was observed, as would be expected. When the laser power was 1.2 W/cm2 the temperature reached 50 °C within 500 s. The photothermal effect is found to be concentration-dependent under irradiation at 0.5 W/cm2 (Fig. 3a2). These results indicate the suitability of MoS2-SS-HA for photothermal therapy and potential for the thermal ablation of tumors. After three on–off cycles of irradiation (Fig. 3b), the temperature response of the MoS2-SS-HA the laser power was 1.2 W/cm2 the temperature reached 50 °C within 500 s. The photothermal effect is found to be concentration-dependent under irradiation at 0.5 W/cm2 (Fig. 3c). These results indicate the suitability of MoS2-SS-HA for photothermal therapy and potent suspension remains largely constant. This suggests that MoS2-SS-HA has excellent photothermal stability.
In vitro drug release
MoS2-SS-HA nanosheet has ultrahigh surface area and a water-soluble biomacromolecule, therefore could be used as a drug carrier [30, 60]. We loaded an insoluble chemotherapeutic drug, erlotinib (Er), on the MoS2-SS-HA nanosheets to obtain the MoS2-SS-HA-Er. It was shown in Fig. 2f that Er had been loaded on the surface of MoS2-SS-HA nanosheets by UV–vis spectra.
Drug release from the nanosheets was affected by many experimental factors [61, 62], the most commonly studied are pH and NIR irradiation. The in vitro release behavior of MoS2-SS-HA-Er was investigated in different pH media (5.6 and 7.4) with and without laser irradiation (Fig. 3c). The release of Er was almost no difference between pH 5.6 and pH 7.4. At a given pH, there is greater Er release with laser irradiation than without. This indicates that NIR light-triggered photothermal heating could promote the release of Er and accelerate the death of cancerous cells. For example, the cumulative release of Er after 12 h at pH 7.4 with laser irradiation (33.3%) was much greater than that at pH 7.4 without laser irradiation (8.9%).
Biocompatibility of MoS2-SS-HA in vitro and in vivo
Biocompatibility is an essential concern when it comes to the development of nanomaterials for biomedical application. An ideal drug delivery platform must be biocompatible, non-toxic and not be associated with incidental adverse effects [62, 63]. Herein, before conducting further experiments in vitro and in vivo, the cytotoxicity of MoS2-SS-HA nanosheets against cells was measured by MTT assay. As shown in Fig. 4a, the viability of all cells remained over 80% at high concentration of MoS2-SS-HA, indicating the ultralow cytotoxicity of MoS2-SS-HA against lung cancer cells (PC-9, A549 and H1975) and HELF cells after 24 h incubation. In addition, hemolysis assay results indicated that negligible hemolysis was observed in MoS2-SS-HA groups, even the concentration reached to 800 μg/mL, demonstrating that the MoS2-SS-HA nanosheets has excellent blood compatibility (Fig. 4b). Further, as shown in Fig. 4c, H&E staining results revealed little histopathological changes between saline group and MoS2-SS-HA group. Hence, good compatibility of the MoS2-SS-HA nanosheets both in vitro and in vivo indicate the great application potential in the cancer treatment.
Cellular uptake in vitro
HA-coated nanoparticles could target the tumor site . The targeting ability of the nanocomposites was investigated by CLSM. A549, H1975 and PC-9 which are HA-receptor positive, while HELF is HA-receptor negative, were cultured with MoS2-SS-HA-FITC and MoS2-SS-HA-FITC + HA, as shown by the coincident presence of DAPI (blue) and FITC (green) fluorescence (Fig. 5a). Relatively little MoS2-SS-HA-FITC is taken up by HA-receptor negative cell line HELF, and a little amount is taken up by erlotinib sensitive cell line PC-9. In contrast, the uptake of MoS2-SS-HA-FITC by erlotinib resistant cell line A549 and H1975 was similar, both exhibiting much greater FITC fluorescence than HELF. This arises because of the lack of an HA receptor on HELF. In order to clarify the cellular uptake mediated by HA receptor, additional HA was added to block CD44 (HA receptor). After HA added, negligible FITC green fluorescence was detected in all cell lines. The quantitative flow cytometry data (Fig. 5b) were consistent with the confocal imaging results, which further indicated MoS2-SS-HA is an excellent CD44-mediated cancer cell targeting drug delivery platform [43, 44, 65,66,67,68].
Cytotoxicity of MoS2-SS-HA-Er in vitro
The therapeutic efficacy of free Er and MoS2-SS-HA-Er against cancer cells was investigated by MTT assays after incubation with PC-9, A549 and H1975 (Fig. 6a). The cell viability of erlotinib-sensitive cell line PC-9 was below 40% with treatment of free Er (20 μg/mL), while the viability of erlotinib-resistant cell line A549 and H1975 is above 60% and 80%, respectively, with treatment at high concentrations of 20 μg/mL free Er, indicating free Er revealed poor therapeutic efficiency against erlotinib-resistant cell lines. The excitement is the viability of erlotinib-resistant cell line (A549 and H1975) decreased below 40% with treatment of MoS2-SS-HA-Er at a concentration of 20 μg/mL. Considering the cell viability at equivalent doses of Er, in the case of A549 and H1975 cells the MoS2-SS-HA-Er group has markedly lower viability than cells treated with the free drug, the reason may be that the nanosystem is embedded in lysomal vesicles by CD44 receptor-mediated endocytosis . To further explore the cell-killing effect of MoS2-SS-HA-Er combined with hyperthermia, cells were incubated with saline (control), Er, MoS2-SS-HA and MoS2-SS-HA-Er at the same Er concentration ([Er] = 10 μg/mL) exposed to the various density of NIR laser irradiation (Fig. 6b). NIR irradiation alone was found to have no effect on cell viability: A549 and H1975 cells showed essentially identical cell viability (> 85%) when they were treated with laser irradiation at a density from 0.5 to 1.2 W/cm2. For all cell types, the viability of cells treated with MoS2-SS-HA-Er ([Er] = 10 μg/mL) and laser irradiation are lower than those receiving MoS2-SS-HA-Er alone, indicating the PTT effect of the MoS2 nanocomposites. The erlotinib-resistant A549 and H1975 cell viabilities in the combined therapy group are much lower than the monotherapy groups (chemotherapy or PTT), showing the synergistic benefits of simultaneous PTT and chemotherapy. This leads to enhanced chemotherapy. Given that the cytotoxic effect of MoS2-SS-HA-Er with or without laser irradiation was higher with A549 and H1975 cells than PC-9 cells, there is also the potential for selective killing of drug-resistance cancer cells. All these results confirm that the multifunctional drug delivery system constructed in this work is effective in killing tumor cells and promising in chemo-photothermal combined cancer therapy.
Cell cycle and cell apoptosis
The result of cells apoptosis assay was illustrated in Fig. 6c. The apoptosis percentages of the cells incubated with MoS2-SS-HA nanosheets were higher than the control group (saline treatment) after irradiation, exhibiting that the MoS2-SS-HA could lead to cell apoptosis depending on the hyperthermia generated by the irradiation. Meanwhile, cells incubated with MoS2-SS-HA-Er were significantly less than the free Er group, verifying the stronger apoptosis effect on CD44-positive cancer cells caused by the MoS2-SS-HA nanosheets. Considering the hypotoxicity of MoS2-SS-HA nanosheets, we believed that the targeting ability played an important role in antitumor effect. Furthermore, after treated with MoS2-SS-HA-Er + NIR, the apoptosis rates of all cells (A549, PC-9, and H1975) were the highest among all groups, demonstrating that the combined therapy remarkably promoted the cell apoptosis. In the cell apoptosis result, the ratio of apoptosis cells in A549, PC-9 and H1975 increased to 24.6%, 36.3% and 23.6%, respectively. The apoptosis cells percentage of MoS2-SS-HA-Er + NIR group was significantly higher than MoS2-SS-HA-Er group and MoS2-SS-HA + NIR group, due to the synergy of chemotherapy and photothermal.
To further explore the mechanism of cell death, the result of cell cycle tested by flow cytometry was analyzed. As indicated in Fig. 6d, compared with the control group, the proportion of cells treated with MoS2-SS-HA + NIR in G0/G1 had no obvious difference, suggesting that the photothermal therapy alone had slight influence on the cell cycle distribution. Cells incubated with MoS2-SS-HA-Er showed the higher arrest percent of G0/G1 compared to the group of free Er, owing to the enhanced intracellular drug uptake mediated by the targeting of HA. After exposed under the 808 nm laser, the cells treated with MoS2-SS-HA-Er + NIR showed the highest ratio of G0/G1-phase because of the synergistic therapeutic effect. In summary, MoS2-SS-HA-Er could enhance the arrest of G0/G1 phase and prevent DNA replication, especially with 808 nm NIR irradiation, while the MoS2-SS-HA + NIR had no such effect. The results of the apoptosis ratio and cell cycle arrest were consistent with the conclusion of MTT assay, suggesting that the MoS2-SS-HA-Er + NIR induced the death of cancer cells through the G0/G1-phase arrest and cell apoptosis induction.
Anti-tumor efficacy in vivo
Encouraged by the synergistic therapeutic effect of MoS2-SS-HA-Er + NIR in vitro, comparative studies of inhibiting tumor effectiveness in vivo was further investigated. In the thermal images (Fig. 7a), the temperature of the tumors on the MoS2-SS-HA and MoS2-SS-HA-Er injected mice quickly increased and could readily reach a level (ΔT = 21 °C) which could induce hyperthermia and heat-induced drug release to kill the tumor. However, the tumor temperature of control (treated with saline) and free Er shows insignificant change (ΔT = 4 °C). Moreover, due to high toxicity always leading to a significant weight loss, the body weight of these mice was measured during the treatments, and no obvious weight loss was observed (Fig. 7b), indicating the low toxicity of the treatments in vivo. The tumor volumes of each group were measured and were then plotted as a function of time (Fig. 7c). Compared with the control group, efficient inhibition of tumor growth is observed for the group treated with MoS2-SS-HA-Er + NIR. Especially, the mean tumor volume in the MoS2-SS-HA-Er + NIR group is the smallest among all treated groups, which demonstrates that MoS2-SS-HA-Er can effectively inhibit tumor growth under the NIR laser irradiation. The reason could be attributed to (i) HA functionalized MoS2-SS-HA-Er targeting tumor site, and (ii) enhanced on-demand release of Er from MoS2-SS-HA-Er after laser irradiation, ultimately inhibiting tumor growth, further (iii) the combination of photothermal with chemotherapy therapy, both of which were activated simultaneously by 808 nm laser.
In summary, a multifunctional MoS2-based drug delivery system (MoS2-SS-HA-Er) was successfully synthesized in this work and shown to allow tumor-targeting synergistic chemo-photothermal therapy. MoS2 nanosheets were modified with the targeting and water-soluble biomacromolecule HA to enhance biocompatibility. The nanocomposite had a uniform diameter (125 nm), and could be loaded with the insoluble anti-cancer drug Er. The release of Er is accelerated under near infrared light irradiation, which is promising for controllable drug delivery system. The nanocomposites can be specifically delivered into cancerous cells via a receptor-mediated endocytosis pathway using hyaluronic acid targeting. The nanocomposites were found to be able to induce the death of cancerous cells while leaving healthy cells unaffected. Furthermore, the MoS2-SS-HA-based drug delivery system can be used for synergistic cancer therapy associated with NIR-mediated hyperthermia and heat-induced local drug release in vitro and in vivo. An effective treatment of lung cancer in vivo under NIR irradiation is obtained, indicating that synergistic efficacy of hyperthermia and chemotherapy is better than hyperthermia or chemotherapy alone.
Availability of data and materials
All data and materials are included in the manuscript.
- MoS2 :
epidermal growth factor receptor
transition metal dichalcogenides
transmission electron microscopy
atomic force microscopy
dynamic laser scattering
Fourier transform infrared
red blood cells
Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220–41.
DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252–71.
Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–89.
Kouranos V, Dimopoulos G, Vassias A, Syrigos KN. Chemotherapy-induced neutropenia in lung cancer patients: the role of antibiotic prophylaxis. Cancer Lett. 2011;313(1):9–14.
Ma Y, Liang XL, Tong S, Bao G, Ren QS, Dai ZF. Gold nanoshell nanomicelles for potential magnetic resonance imaging, light-triggered drug release, and photothermal therapy. Adv Funct Mater. 2013;23(7):815–22.
Chen J, Smith M, Kolinsky K, Adames V, Mehta N, Fritzky L, Rashed M, Wheeldon E, Linn M, Higgins B. Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models. Cancer Chemother Pharmacol. 2007;59(5):651–9.
Cataldo VD, Gibbons DL, Perez-Soler R, Quintas-Cardama A. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med. 2011;364(10):947–55.
Schwendener RA. Liposomes in biology and medicine. Adv Exp Med Biol. 2007;620:117–28.
Anderson T, Hu R, Yang CB, Yoon HS, Yong KT. Pancreatic cancer gene therapy using an siRNA-functionalized single walled carbon nanotubes (SWNTs) nanoplex. Biomater Sci-Uk. 2014;2(9):1244–53.
Tarn D, Ashley CE, Xue M, Carnes EC, Zink JI, Brinker CJ. Mesoporous silica nanoparticle nanocarriers: biofunctionality and biocompatibility. Acc Chem Res. 2013;46(3):792–801.
Yin F, Yang CB, Wang QQ, Zeng SW, Hu R, Lin GM, Tian JL, Hu SY, Lan RF, Yoon HS, et al. A light-driven therapy of pancreatic adenocarcinoma using gold nanorods-based nanocarriers for co-delivery of doxorubicin and siRNA. Theranostics. 2015;5(8):818–33.
Parveen S, Sahoo SK. Polymeric nanoparticles for cancer therapy. J Drug Target. 2008;16(2):108–23.
Houdaihed L, Evans JC, Allen C. Overcoming the road blocks: advancement of block copolymer micelles for cancer therapy in the clinic. Mol Pharm. 2017;14(8):2503–17.
Vogus DR, Evans MA, Pusuluri A, Barajas A, Zhang M, Krishnan V, Nowak M, Menegatti S, Helgeson ME, Squires TM, et al. A hyaluronic acid conjugate engineered to synergistically and sequentially deliver gemcitabine and doxorubicin to treat triple negative breast cancer. J Control Release. 2017;267:191–202.
Wu C, Guan X, Xu J, Zhang Y, Liu Q, Tian Y, Li S, Qin X, Yang H, Liu Y. Highly efficient cascading synergy of cancer photo-immunotherapy enabled by engineered graphene quantum dots/photosensitizer/CpG oligonucleotides hybrid nanotheranostics. Biomaterials. 2019;205:106–19.
Kim MW, Jeong HY, Kang SJ, Jeong IH, Choi MJ, You YM, Im CS, Song IH, Lee TS, Lee JS, et al. Anti-EGF receptor aptamer-guided co-delivery of anti-cancer siRNAs and quantum dots for theranostics of triple-negative breast cancer. Theranostics. 2019;9(3):837–52.
Adamson P. Reflectance calculations of anisotropic dielectric constants of graphene-like two-dimensional materials. Appl Opt. 2017;56(28):7832–40.
Wang H, Feng H, Li J. Graphene and graphene-like layered transition metal dichalcogenides in energy conversion and storage. Small. 2014;10(11):2165–81.
Li MY, Shi Y, Cheng CC, Lu LS, Lin YC, Tang HL, Tsai ML, Chu CW, Wei KH, He JH, et al. Nanoelectronics. Epitaxial growth of a monolayer WSe2-MoS2 lateral p–n junction with an atomically sharp interface. Science. 2015;349(6247):524–8.
Xiong F, Wang H, Liu X, Sun J, Brongersma M, Pop E, Cui Y. Li intercalation in MoS2: in situ observation of its dynamics and tuning optical and electrical properties. Nano Lett. 2015;15(10):6777–84.
Liu QH, Li LZ, Li YF, Gao ZX, Chen ZF, Lu J. Tuning electronic structure of bilayer MoS2 by vertical electric field: a first-principles investigation. J Phys Chem C. 2012;116(40):21556–62.
Leong WS, Li Y, Luo X, Nai CT, Quek SY, Thong JT. Tuning the threshold voltage of MoS2 field-effect transistors via surface treatment. Nanoscale. 2015;7(24):10823–31.
Kappera R, Voiry D, Yalcin SE, Branch B, Gupta G, Mohite AD, Chhowalla M. Phase-engineered low-resistance contacts for ultrathin MoS2 transistors. Nat Mater. 2014;13(12):1128–34.
Lee Y, Lee J, Kim S, Park HS. Rendering high charge density of states in ionic liquid-gated MoS2 transistors. J Phys Chem C. 2014;118(31):18278–82.
Kalluri S, Seng KH, Guo Z, Du A, Konstantinov K, Liu HK, Dou SX. Sodium and lithium storage properties of spray-dried molybdenum disulfide-graphene hierarchical microspheres. Sci Rep. 2015;5:11989.
Rao CN, Gopalakrishnan K, Maitra U. Comparative study of potential applications of graphene, MoS2, and other two-dimensional materials in energy devices, sensors, and related areas. ACS Appl Mater Interfaces. 2015;7(15):7809–32.
Cuddy MJ, Arkill KP, Wang ZW, Komsa HP, Krasheninnikov AV, Palmer RE. Fabrication and atomic structure of size-selected, layered MoS2 clusters for catalysis. Nanoscale. 2014;6(21):12463–9.
Deng ZH, Li L, Ding W, Xiong K, Wei ZD. Synthesized ultrathin MoS2 nanosheets perpendicular to graphene for catalysis of hydrogen evolution reaction. Chem Commun. 2015;51(10):1893–6.
Voiry D, Salehi M, Silva R, Fujita T, Chen MW, Asefa T, Shenoy VB, Eda G, Chhowalla M. Conducting MoS2 nanosheets as catalysts for hydrogen evolution reaction. Nano Lett. 2013;13(12):6222–7.
Liu T, Wang C, Gu X, Gong H, Cheng L, Shi X, Feng L, Sun B, Liu Z. Drug delivery with PEGylated MoS2 nano-sheets for combined photothermal and chemotherapy of cancer. Adv Mater. 2014;26(21):3433–40.
Wang S, Li K, Chen Y, Chen H, Ma M, Feng J, Zhao Q, Shi J. Biocompatible PEGylated MoS2 nanosheets: controllable bottom-up synthesis and highly efficient photothermal regression of tumor. Biomaterials. 2015;39:206–17.
Chen YW, Su YL, Hu SH, Chen SY. Functionalized graphene nanocomposites for enhancing photothermal therapy in tumor treatment. Adv Drug Deliver Rev. 2016;105:190–204.
Zou LL, Wang H, He B, Zeng LJ, Tan T, Cao HQ, He XY, Zhang ZW, Guo SR, Li YP. Current approaches of photothermal therapy in treating cancer metastasis with nanotherapeutics. Theranostics. 2016;6(6):762–72.
Chou SS, Kaehr B, Kim J, Foley BM, De M, Hopkins PE, Huang J, Brinker CJ, Dravid VP. Chemically exfoliated MoS2 as near-infrared photothermal agents. Angew Chem Int Edit. 2013;52(15):4160–4.
Tan L, Wang S, Xu K, Liu T, Liang P, Niu M, Fu C, Shao H, Yu J, Ma T, et al. Layered MoS2 hollow spheres for highly-efficient photothermal therapy of rabbit liver orthotopic transplantation tumors. Small. 2016;12(15):2046–55.
Liu T, Shi SX, Liang C, Shen SD, Cheng L, Wang C, Song XJ, Goel S, Barnhart TE, Cai WB, et al. Iron oxide decorated MoS2 nanosheets with double PEGylation for chelator-free radio labeling and Multimodal imaging guided photothermal therapy. ACS Nano. 2015;9(1):950–60.
Radisavljevic B, Kis A. Measurement of mobility in dual-gated MoS2 transistors. Nat Nanotechnol. 2013;8(3):147–8.
Late DJ, Liu B, Matte HSSR, Dravid VP, Rao CNR. Hysteresis in single-layer MoS2 field effect transistors. ACS Nano. 2012;6(6):5635–41.
Chou SS, De M, Kim J, Byun S, Dykstra C, Yu J, Huang JX, Dravid VP. Ligand conjugation of chemically exfoliated MoS2. J Am Chem Soc. 2013;135(12):4584–7.
Saha N, Dubey AK, Basu B. Cellular proliferation, cellular viability, and biocompatibility of HA-ZnO composites. J Biomed Mater Res B Appl Biomater. 2012;100(1):256–64.
Liao YH, Jones SA, Forbes B, Martin GP, Brown MB. Hyaluronan: pharmaceutical characterization and drug delivery. Drug Deliv. 2005;12(6):327–42.
Luo Y, Wang X, Du D, Lin Y. Hyaluronic acid-conjugated apoferritin nanocages for lung cancer targeted drug delivery. Biomater Sci. 2015;3(10):1386–94.
Mattheolabakis G, Milane L, Singh A, Amiji MM. Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine. J Drug Target. 2015;23(7–8):605–18.
Quan YH, Kim B, Park JH, Choi Y, Choi YH, Kim HK. Highly sensitive and selective anticancer effect by conjugated HA-cisplatin in non-small cell lung cancer overexpressed with CD44. Exp Lung Res. 2014;40(10):475–84.
Zhong YN, Zhang J, Cheng R, Deng C, Meng FH, Xie F, Zhong ZY. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts. J Control Release. 2015;205:144–54.
Joensen P, Frindt RF, Morrison SR. Single-layer Mos2. Mater Res Bull. 1986;21(4):457–61.
Li F, Mei H, Gao Y, Xie X, Nie H, Li T, Zhang H, Jia L. Co-delivery of oxygen and erlotinib by aptamer-modified liposomal complexes to reverse hypoxia-induced drug resistance in lung cancer. Biomaterials. 2017;145:56–71.
Jiang K, Chi T, Li T, Zheng G, Fan L, Liu Y, Chen X, Chen S, Jia L, Shao J. A smart pH-responsive nano-carrier as a drug delivery system for the targeted delivery of ursolic acid: suppresses cancer growth and metastasis by modulating P53/MMP-9/PTEN/CD44 mediated multiple signaling pathways. Nanoscale. 2017;9(27):9428–39.
Zheng G, Shen Z, Chen H, Liu J, Jiang K, Fan L, Jia L, Shao J. Metapristone suppresses non-small cell lung cancer proliferation and metastasis via modulating RAS/RAF/MEK/MAPK signaling pathway. Biomed Pharmacother. 2017;90:437–45.
Liu H, Xu L, Liu W, Zhou B, Zhu Y, Zhu L, Jiang X. Production of mono- to few-layer MoS2 nanosheets in isopropanol by a salt-assisted direct liquid-phase exfoliation method. J Colloid Interface Sci. 2018;515:27–31.
Stergiou A, Tagmatarchis N. Molecular functionalization of 2D MoS2 nanosheets. Chemistry. 2018;24:18246.
Wu JR, Bremner DH, Niu SW, Wu HL, Wu JZ, Wang HJ, Li HY, Zhu LM. Functionalized MoS2 nanosheet-capped periodic mesoporous organosilicas as a multifunctional platform for synergistic targeted chemo-photothermal therapy. Chem Eng J. 2018;342:90–102.
Tan S, Wang G. Redox-responsive and pH-sensitive nanoparticles enhanced stability and anticancer ability of erlotinib to treat lung cancer in vivo. Drug Des Devel Ther. 2017;11:3519–29.
Chen H, Qin J, Hu Y. Efficient degradation of high-molecular-weight hyaluronic acid by a combination of ultrasound, hydrogen peroxide, and copper ion. Molecules. 2019;24(3):E617.
Hafsa J, Chaouch MA, Charfeddine B, Rihouey C, Limem K, Le Cerf D, Rouatbi S, Majdoub H. Effect of ultrasonic degradation of hyaluronic acid extracted from rooster comb on antioxidant and antiglycation activities. Pharm Biol. 2017;55(1):156–63.
Lam AT, Yoon J, Ganbold EO, Singh DK, Kim D, Cho KH, Son SJ, Choo J, Lee SY, Kim S, et al. Adsorption and desorption of tyrosine kinase inhibitor erlotinib on gold nanoparticles. J Colloid Interface Sci. 2014;425:96–101.
Rasoulzadeh F, Asgari D, Naseri A, Rashidi MR. Spectroscopic studies on the interaction between erlotinib hydrochloride and bovine serum albumin. Daru. 2010;18(3):179–84.
Cao H, Huang Y, Xie Y, Shi W, Fu C, He W. A fast-responsive fluorescent probe for sensitive detection of graphene oxide based on MoS2 quantum dots. Analyst. 2018;143(13):3107–13.
Shi JW, Zou Y, Ma D, Fan Z, Cheng L, Sun D, Wang Z, Niu C, Wang L. Stable 1T-phase MoS2 as an effective electron mediator promoting photocatalytic hydrogen production. Nanoscale. 2018;10(19):9292–303.
Schopper C, Moser D, Spassova E, Goriwoda W, Lagogiannis G, Hoering B, Ewers R, Redl H. Bone regeneration using a naturally grown HA/TCP carrier loaded with rh BMP-2 is independent of barrier-membrane effects. J Biomed Mater Res A. 2008;85(4):954–63.
Lin Y, Zhou Q, Li J, Shu J, Qiu Z, Lin Y, Tang D. Magnetic graphene nanosheet-based microfluidic device for homogeneous real-time electronic monitoring of pyrophosphatase activity using enzymatic hydrolysate-induced release of copper ion. Anal Chem. 2016;88(1):1030–8.
Yang L, Sun H, Liu Y, Hou W, Yang Y, Cai R, Cui C, Zhang P, Pan X, Li X, et al. Self-assembled aptamer-grafted hyperbranched polymer nanocarrier for targeted and photoresponsive drug delivery. Angew Chem Int Ed Engl. 2018;57(52):17048–52.
Schwarzenbock C, Nelson PJ, Huss R, Rieger B. Synthesis of next generation dual-responsive cross-linked nanoparticles and their application to anti-cancer drug delivery. Nanoscale. 2018;10(34):16062–8.
Xiong H, Du S, Ni J, Zhou J, Yao J. Mitochondria and nuclei dual-targeted heterogeneous hydroxyapatite nanoparticles for enhancing therapeutic efficacy of doxorubicin. Biomaterials. 2016;94:70–83.
Alamgeer M, Neil Watkins D, Banakh I, Kumar B, Gough DJ, Markman B, Ganju V. A phase IIa study of HA-irinotecan, formulation of hyaluronic acid and irinotecan targeting CD44 in extensive-stage small cell lung cancer. Invest New Drugs. 2018;36(2):288–98.
Song JM, Molla K, Anandharaj A, Cornax I, Kirtane AR, Panyam J, Kassie F. Triptolide suppresses the in vitro and in vivo growth of lung cancer cells by targeting hyaluronan-CD44/RHAMM signaling. Oncotarget. 2017;8(16):26927–40.
Talekar M, Trivedi M, Shah P, Ouyang Q, Oka A, Gandham S, Amiji MM. Combination wt-p53 and MicroRNA-125b transfection in a genetically engineered lung cancer model using dual CD44/EGFR-targeting nanoparticles. Mol Ther. 2016;24(4):759–69.
Jeannot V, Mazzaferro S, Lavaud J, Vanwonterghem L, Henry M, Arboleas M, Vollaire J, Josserand V, Coll JL, Lecommandoux S, et al. Targeting CD44 receptor-positive lung tumors using polysaccharide-based nanocarriers: Influence of nanoparticle size and administration route. Nanomedicine. 2016;12(4):921–32.
Liu C, Chen Z, Wang Z, Li W, Ju E, Yan Z, Liu Z, Ren J, Qu X. A graphitic hollow carbon nitride nanosphere as a novel photochemical internalization agent for targeted and stimuli-responsive cancer therapy. Nanoscale. 2016;8(25):12570–8.
Ethics approval and consent to participate
The protocols and the use of animals were approved by and in accordance with the University of Fuzhou Animal Care and Use Committee.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.